Medicare proposes limiting coverage of controversial Alzheimer's drug

Jan 13, 2022
Government insurer won't cover Aduhelm's $28,000-a-year price tag except for clinical trials.
A sign for biotechnology company, Biogen, Inc. is seen on a building in Cambridge, Massachusetts.
DOMINICK REUTER/AFP via Getty Images

Need some Econ 101?

Our new Marketplace Crash Course is here to help. Sign-up for free, learn at your own pace.